Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Flexion Therapeutics (FLXN) a Smart Long-term Buy?

Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download here. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller Value Partners top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.

In the said letter, Miller Value Partners highlighted a few stocks and Flexion Therapeutics Inc (NASDAQ:FLXN) is one of them. Flexion Therapeutics is a biopharmaceutical company. Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 45.9% and on June 10th it had a closing price of $11.88. Here is what Miller Value Partners said:

“Flexion Therapeutics (FLXN) fell 62.0% during the quarter as people became concerned with their ability to reach profitability without having to raise capital due to negative sales impact from COVID-19. The company reported Q4 revenue of $23.7M (+148% Year-over-Year (Y/Y)), in-line with their pre-announcement. The company announced a licensing deal with Hong Kong Tainuo Pharma for development and commercialization of Zilretta in Greater China with a $10M upfront payment and up to $32.5Min milestones. At the same time, the company withdrew its 2020 guidance and noted the suspension of certain clinical trials to maintain safety during the COVID-19 outbreak.”

Easiest Md/PhD Programs to Get Into

Our calculations showed that Flexion Therapeutics Inc (NASDAQ:FLXN) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, 2020’s unprecedented market conditions provide us with the highest number of trading opportunities in a decade. So we are checking out stocks recommended/scorned by legendary Bill Miller. We interview hedge fund managers and ask them about their best ideas. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. Our best call in 2020 was shorting the market when the S&P 500 was trading at 3150 after realizing the coronavirus pandemic’s significance before most investors. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.